/ONCO
ONCO Stock - Onconetix, Inc.
Healthcare|BiotechnologyNASDAQ
$1.77-3.80%
$0.07 (-3.80%) • Dec 19
35
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.95
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ONCO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.75 – $1.79
TARGET (TP)$2.04
STOP LOSS$1.63
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.42
52W High$179.35
52W Low$1.77
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.52M | $58,465 | N/A | N/A | N/A |
| Gross Profit | $1.06M | $-1,127,165 | $-6,752 | $-4,890 | $-3,056 |
| Gross Margin | 41.8% | -1927.9% | N/A | N/A | N/A |
| Operating Income | $-56,488,755 | $-36,034,595 | $-13,481,240 | $-3,417,334 | $-1,622,069 |
| Net Income | $-58,691,023 | $-37,409,694 | $-13,419,830 | $-3,417,334 | $-1,599,466 |
| Net Margin | -2325.2% | -63986.5% | N/A | N/A | N/A |
| EPS | $-1823.25 | $-87.60 | $-1.09 | $-0.31 | $-0.14 |
Company Overview
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ONCOBeat Rate
60%
Last 5 quarters
Avg Surprise
+9.2%
EPS vs Estimate
Beats / Misses
3/2
Last 12 quarters
Latest EPS
$-6.25
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
+23.8%
$-6.40vs$-8.40
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Jun 1, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-6.25 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-4.05 | — | — |
Q2 2025 | Jun 12, 2025 | — | $21.19 | — | — |
Q2 2025 | Jun 2, 2025 | — | $-6.40 | — | — |
Q4 2024 | Dec 9, 2024 | — | $-2.24 | — | — |
Q3 2024 | Aug 29, 2024 | — | $-9.20 | — | — |
Q2 2024 | May 20, 2024 | $-8.40 | $-6.40 | +23.8% | ✓ BEAT |
Q1 2024 | Mar 9, 2024 | — | $-1.00 | — | — |
Q4 2023 | Nov 17, 2023 | $-0.19 | $-0.28 | -47.4% | ✗ MISS |
Q4 2023 | Oct 20, 2023 | $-0.19 | $-0.43 | -126.3% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-8.20 | $-0.18 | +97.8% | ✓ BEAT |
Q4 2022 | Dec 30, 2022 | $-10.60 | $-0.21 | +98.0% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | — | $-0.27 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-0.36 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.33 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.11 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.10 | — | — |
Q1 2021 | Mar 30, 2021 | — | $-0.10 | — | — |
Latest News
Onconetix Q3 EPS $(6.25) Up From $(249.05) YoY, Sales $303.651K Down From $406.859K YoY
📉 NegativeBenzinga•Nov 13, 2025, 10:29 PM
Onconetix Files Prospectus For Resale Of 22.1M Shares Of Common Stock By Selling Stockholders
📉 NegativeBenzinga•Nov 4, 2025, 10:44 PM
ONCO stock has given up its prior gain. Onconetix shares were trading higher after the company announced it settled its debt with Veru and terminated its merger agreement with Ocuvex.
📉 NegativeBenzinga•Sep 26, 2025, 01:03 PM
Onconetix Announces $12.9M Private Placement of Series D Preferred Stock And Warrants; Terminates Ocuvex Merger Agreement; Settles $8.8M Debt With Veru
➖ NeutralBenzinga•Sep 26, 2025, 12:31 PM
Onconetix's Proteomedix Licenses Key Antibody Technology To Immunovia For Pancreatic Cancer Test; In Return, Immunovia Will Make Payments Totaling $700K To Proteomedix In 2025 And 2026, As Well As Pay A 3% Royalty On Net Sales Of PancreaSure And Any Other Products Incorporating The Licensed Intellectual Property From 2026 To 2032
📈 PositiveBenzinga•Sep 22, 2025, 12:16 PM
Onconetix to buy privately held Ocuvex Therapeutics
📈 PositiveSeeking Alpha•Jul 16, 2025, 02:12 PM
Onconetix announces 1-for-85 reverse stock split
📉 NegativeSeeking Alpha•Jun 11, 2025, 03:46 PM
Frequently Asked Questions about ONCO
What is ONCO's current stock price?
Onconetix, Inc. (ONCO) is currently trading at $1.77 per share. The stock has moved -3.80% today.
What is the analyst price target for ONCO?
No analyst price targets are currently available for this stock.
What sector is Onconetix, Inc. in?
Onconetix, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ONCO's market cap?
Onconetix, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ONCO pay dividends?
No, Onconetix, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZTR
Azitra, Inc.
$0.29
Mkt Cap: $0.0B
ENVB
Enveric Biosciences, Inc.
$5.08
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
PTIX
Protagenic Therapeutics, Inc.
$1.19
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SCNI
Scinai Immunotherapeutics Ltd.
$0.79
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
SPRC
SciSparc Ltd.
$1.46
Mkt Cap: $0.0B
Explore stocks similar to ONCO for comparison